Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Saved in:
| Title: | Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. |
|---|---|
| Authors: | Gadelha MR; Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro CEP 21941-913, Brazil., Casagrande A; Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA., Strasburger CJ; Department of Medicine for Endocrinology and Metabolic Disorders, Charité Universitaetsmedizin, Berlin 10117, Germany., Bidlingmaier M; Neuroendocrine Research Group, Department of Internal Medicine, Ludwig-Maximilians University, Munich 80336, Germany., Snyder PJ; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Guitelman MA; División Endocrinología, Hospital Carlos G. Durand, Buenos Aires 1405, Argentina., Boguszewski CL; Department of Internal Medicine, Endocrine Division (SEMPR), University Hospital, Federal University of Paraná, Curitiba 80030-110, Brazil., Buchfelder M; Neurosurgery Department, University Hospital Erlangen, Erlangen 91054, Germany., Shimon I; Rabin-Beilinson Medical Center, Institute of Endocrinology, Petach Tikva 4941492, Israel.; Faculty of Medical and Health Sciences, School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Raverot G; Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, 'Groupement Hospitalier Est' Hospices Civils de Lyon, Lyon Cedex 69002, France., Tóth M; Department of Internal Medicine and Oncology, Semmelweis University, Budapest 1083, Hungary., Mezősi E; Department of Medicine, University of Pécs Medical School, Pécs 7624, Hungary., Doknic M; Neuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade 11000, Serbia., Fan X; Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA., Clemmons D; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27514, USA., Trainer PJ; Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA., Struthers RS; Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA., Krasner A; Crinetics Pharmaceuticals, Inc., San Diego, CA 92121, USA., Biller BMK; Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA 02114, USA. |
| Source: | The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Dec 18; Vol. 110 (1), pp. 228-237. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication Model: Print Cited Medium: Internet ISSN: 1945-7197 (Electronic) Linking ISSN: 0021972X NLM ISO Abbreviation: J Clin Endocrinol Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1945-7197 |
|---|---|
| DOI: | 10.1210/clinem/dgae385 |
